Amphotericin B topical - DNDi/Humax Pharmaceutical/Universidad de Antioquia/PECET

Drug Profile

Amphotericin B topical - DNDi/Humax Pharmaceutical/Universidad de Antioquia/PECET

Alternative Names: Anfoleish

Latest Information Update: 20 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Drugs for Neglected Diseases Initiative Foundation; Humax Pharmaceutical; Universidad de Antioquia
  • Developer Drugs for Neglected Diseases Initiative Foundation; Humax Pharmaceutical; Program for the Study and Control of Tropical Diseases; Universidad de Antioquia
  • Class Antifungals; Antiprotozoals; Macrolides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cutaneous leishmaniasis

Most Recent Events

  • 01 Jul 2016 DNDi completes a phase I/IIb trial in Cutaneous leishmaniasis in Colombia (NCT01845727)
  • 29 Apr 2016 Biomarkers information updated
  • 18 Dec 2015 Phase-Ib/II development for Cutaneous leishmaniasis is ongoing in Colombia (NCT01845727)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top